Company Interview / Deal done to fund 'East-West' model without tapping shareholders

Tim Oldham, CEO of AdAlta (ASX:1AD) explains AdAlta's (ASX:1AD) collaboration with Synthesis Bio Ventures, aiming to bridge Asian innovations to Western markets. He reveals that Synthesis, founded by Andrew Wilks, has spearheaded projects enabling cross-border transactions, specifically between China and Australia.

AdAlta (ASX:1AD) is working on its 'east-west' model to tap into the potential of reprogramming immune cells to tackle solid cancers, following promising outcomes in blood cancer treatments. He highlights how 60% of clinical trials in cellular immunotherapies occur in Asia, emphasising Australia's role in this innovation.

AdAlta's (ASX:1AD) execution of private investment opportunities for its East-West cellular immunotherapy strategy provides a capital-efficient model for AdAlta (ASX:1AD) shareholders, offering growth potential without needing additional shareholder funds.